CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate Cancer
Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, open label, randomized study. Patients will be randomized to one of
the following arms with an allocation ratio of 3:1, respectively: Arm A: CP-675,206 +
neoadjuvant hormone therapy (NHT) OR Arm B: neoadjuvant hormone therapy. After randomization,
patients will receive study treatment for three cycles (one cycle is defined as 28 days).
After completion of three cycles, patients will undergo a prostatectomy and pathology
assessments will be completed at a central laboratory, the Armed Forces Institute of
Pathology (AFIP) in Washington, DC.